Index

Note: Page numbers of article titles are in boldface type.

A
Abdominal obesity
  definition of, 921
  insulin resistance relationship with, 878–884
Adipocytes
  dysfunction of, in obesity, 897–898
  in hypertension, 908
Adiponectin
  in dyslipidemia, 897–898
  in hypertension, 910–911
  in metabolic syndrome, 863–864
Agouti-related peptide, in lipid metabolism, 898
Akt protein, in metabolic syndrome, 861
Albuminemia, cardiovascular disease in, 929–930
Aldosterone, in hypertension, 905–906, 912
American Association of Clinical Endocrinologists, metabolic syndrome
  definition of, 856–857
American Heart Association, metabolic syndrome criteria of, 857–858
AMPK-sensitive protein kinase, in exercise, 955, 958
Angiotensin, in hypertension, 905–906, 912
Angiotensinogen, in hypertension, 908
Arcuate nucleus, lipid metabolism regulation in, 898
Atkins diet, 941–943
Atrial fibrillation, 923–924

B
Banting diet, 941–943
Bariatric surgery, 1009–1030
  diabetes remission after, 1023–1025
  effect on obesity-related comorbidities, 1018–1022
  facility requirements for, 1011–1012
  impact on mortality, 1017–1018
  outcomes of, 1016–1022
  patient selection for, 1011
  procedures for, 1012–1016
  results of, 1010–1011
Baroreflex dysfunction, in hypertension, 906
Behavioral modification. See Cognitive-behavioral therapy.
Behavioral Risk Factor Surveillance System data, on weight loss, 972
Benzphetamine, 991, 993–994
Biliopancreatic diversion and duodenal switch, 1015–1017, 1021

Body mass index
  cardiovascular disease risk and, 883–884
  insulin resistance relationship with, 878–880

Bogalusa Heart Study, 921

Brain, lipid metabolism regulation in, 898

Bupropion, 997, 1003

Bypass Angioplasty revascularization Investigation trial, 925

C

Calcium supplementation, for weight loss, 944–945

Caloric restriction, diabetes mellitus remission in, 1023

Cannabinoid system, in metabolic syndrome, 864

Cardiovascular disease, 919–937
  atrial fibrillation, 923–924
  coronary artery disease, 920–922
  diabetes mellitus and. See Diabetes mellitus.
  dyslipidemia, 893–902, 927–928
  heart failure, 922–923
  hypertension. See Hypertension.
  insulin resistance relationship with
    abdominal obesity and, 883–885
    fitness and, 876–877
    weight loss effects on, 885–888
  metabolic syndrome and, 859–860, 928
  obesity distribution and, 921
  outcome paradox and, 924–925
  risk factors for, 921–922, 928–931

Carotid Intima Media Thickness in Atherosclerosis Using Pioglitazone trial, 919

CART (cocaine- and amphetamine-regulated transcript), in lipid metabolism, 898

Cetilistat, 1003

C-jun N terminal kinase, in metabolic syndrome, 862–863

Coagulopathy, cardiovascular disease in, 929–930

Cocaine- and amphetamine-regulated transcript, in lipid metabolism, 898

Cognitive-behavioral therapy, 971–988
  cognitive restructuring in, 977
  description of, 972–973
  efficacy of, 977–979
  environmental changes in, 974
  evidence for, 972–973
  goal setting in, 973
  motivational readiness for, 978
  patient expectations for, 976
  problem solving in, 974–975
  relapse prevention in, 975
  self-monitoring in, 973–974
  stimulus control in, 974
  strategies for, 976–977
terminology subtle distinction in, 975–976
weight-loss maintenance complexities and, 979–981
Coronary artery disease, 920–922
Corticosteroids
  in hypertension, 909–910
  in metabolic syndrome, 864–865
C-reactive protein, in cardiovascular disease, 930
CREB protein, in exercise, 958
Cytokines
  in cardiovascular disease, 930
  in hypertension, 908
  in metabolic syndrome, 862–864

D
Dairy products, for weight loss, 944–945
Diabetes mellitus
  bariatric surgery effects on, 1018–1025
  cardiovascular disease risk in, 925–926
  exercise for, 953–959
  in hypertension, 906–907
  in metabolic syndrome, 859–860
Diabetes Prevention Program, for metabolic syndrome, 865–866
Diacylglycerol accumulation, in exercise, 957
Diet, for obesity, 939–952
  calcium supplementation, 944–945
  cognitive-behavioral aspects of, 972–979
  dairy products, 944–945
  facilitation of, 947
  for maintenance, 945–946
  low glycemic index, 943–944
  low-carbohydrate, 941–943
  low-fat, 941–943
  types of, 941–945
  versus increased physical activity, 940–941
Diethylpropion, 991, 993–994
Drugs, for weight reduction, 989–1008
  clinical trials of, 1000–1003
  combinations of, 1003
  increasing energy expenditure, 1003
  not approved, 996–1000
  reducing fat absorption, 994–996
  with central nervous system action, 990–994
Dyslipidemia, obesity-associated, 893–902
  adipocyte dysfunction in, 897–898
  cardiovascular disease and, 927–928
  in metabolic syndrome, 855–858, 866
  lipid composition in, 896–897
  lipid metabolism regulation in, 898
  pathogenesis of, 895–896
Dyslipidemia (*continued*)
   treatment of, 866
   versus normal lipid metabolism, 894–895

E
Endothelial dysfunction
   cardiovascular disease in, 929
   in obstructive sleep apnea, 911–912
Endothelins, in hypertension, 909
Energy deficit, for weight loss, 940–941
Energy gap, 980–981
Energy requirements
   drugs increasing, 1003
      of formerly obese persons, 945–946
Environmental factors, in cognitive-behavioral therapy, 974
Epierenone, for hypertension, 906
European Group for the Study of Insulin Resistance, 856, 877–878
European Prospective Investigation into Cancer Norfolk study, hypertension
   statistics in, 903
Exenatide, 999–1000
Exercise, 953–969
   goals of, 953–954
   muscle effects of, 954–960
   programs for, 953–954
   recommendations for, 960–961
   variations in adiposity and, 877
   versus diet, 940–941

F
Fatty acids
   free, in hypertension, 909
      metabolism of, exercise and, 955–957
      nonesterified, in metabolic syndrome, 862
Fenfluramine, 1002–1003
Fenofibrate, for dyslipidemia, 866
Fenofibrate Interventions and Event-Lowering in Diabetes study, 928
Fibrates, for dyslipidemia, 866, 927–928
Fibrinolysis, abnormal, cardiovascular disease in, 929
Finnish Diabetes Prevention Study, 865–866
Fitness, among obese people, 876–877
Fluoxetine, 996–997

G
Gastrectomy, sleeve, 1015, 1017
Gastric banding, laparoscopic adjustable, 1014–1017, 1019
Gastric bypass
   laparoscopic, 1016–1017, 1029
   Roux-en-Y, 1012–1014, 1020
Gastroplasty, vertical banded, 1012
Gemfibrozil, for dyslipidemia, 866
Genetic factors, in muscle response to exercise, 960
Ghrelin
   after bariatric surgery, 1024–1025
   in lipid metabolism, 898
Glomerulopathy, in hypertension, 908
Glucose tolerance, impaired, in metabolic syndrome, 855–858
Glucose transporters, in metabolic syndrome, 861–864
Glucose uptake, insulin-mediated
   cardiovascular risk and, 886–888
   fitness and, 876–877
   obesity and, 877–878
   visceral obesity and, 880–882
Glycemic index, diets based on, 943–944
Growth hormone, in metabolic syndrome, 864–865

H
Heart failure, 922–923
11-beta-Hydroxysteroid dehydrogenase type 1, in hypertension, 909–910
Hyperinsulinemia
   in hypertension, 906
   in metabolic syndrome, 855–858
Hypertension
   in metabolic syndrome, 855–858, 863
   in obesity, 903–917, 926–927
      adiposity and, 908–911
      insulin resistance and, 906–907
      mechanisms of, 904–905
      obstructive sleep apnea and, 911–912
      prevalence of, 903–904
      renal changes in, 907–908
      renin angiotensin aldosterone system and, 905–906
      sympathetic nervous system and, 906
Hypothalamic-pituitary axis, dysfunction of, in hypertension, 906
Hypothalamus, lipid metabolism regulation in, 898

I
Inflammation, cardiovascular disease in, 929–930
Institute of Medicine, exercise recommendations of, 961
Insulin receptors, in metabolic syndrome, 861–864
Insulin resistance, 875–892
   after bariatric surgery, 1024
   cardiovascular disease in, 883–888, 929
   dyslipidemia in, 895–896
   exercise and, 956–957
   fitness and, 876–877
   glycemic index and, 943–944
   in hypertension, 906–907
Insulin (continued)
  in metabolic syndrome, 855–858
  in weight loss, 885–888
  obesity and, 877–888
  waist circumference and, 878–884
INTERHEART Study, 921–922
Interleukin(s)
  in dyslipidemia, 897–898
  in metabolic syndrome, 862–864
International Association for the Study of Obesity, exercise recommendations of, 961
International Diabetes Federation, metabolic syndrome definition of, 857
International Diabetes Foundation, metabolic syndrome definition of, 893–894

J
Justification for the Use of Statins in Primary Prevention (JUPITER) trial, 930

K
Kidney, dysfunction of, in hypertension, 907–908

L
Lamotrigine, 998
Laparoscopic adjustable gastric banding, 1014–1017, 1019
Laparoscopic gastric bypass, 1016–1017, 1029
Laparoscopic Roux-en-Y gastric bypass, 1012–1014
LEARN diet, 942
Leptin
  after bariatric surgery, 1025
  in dyslipidemia, 897
  in hypertension, 906, 908, 910
  in lipid metabolism, 898
  in metabolic syndrome, 863
Lifestyle modifications
  exercise as, 940–941, 953–969
  for metabolic syndrome, 865–866
Lipid(s)
  disorders of. See Dyslipidemia, obesity-associated.
  normal metabolism of, 894–895
  oxidation of, in exercise, 955
Lipoproteins
  composition of, in dyslipidemia, 895–896
  normal metabolism of, 894–895
Lisinopril, for hypertension, 906
Low-carbohydrate diet, 941–943
Low-fat diet, 941–943

M
Maintenance programs, for weight loss
  cognitive-behavioral therapy, 979–981
diets, 945–946
Mediterranean diet, 942
Metabolic syndrome, 855–873
  cardiovascular disease and, 928
  clinical approach to, 865–866
  components of, 855–858
  definitions of, 857–858, 893–894
  former names of, 855–856
  historical overview of, 855–857
  pathogenesis of, 860–865
  prevalence of, 858–859
  prognosis for, 859–860
Metformin
  for metabolic syndrome, 865–866
  for weight loss, 999
Microalbuminemia, cardiovascular disease in, 929–930
Mitochondrial dysfunction, exercise and, 957–960
Mitogen-activated protein kinase, in metabolic syndrome, 861
Motivational readiness, for weight treatment, 976
Muscle(s), exercise effects on, 954–960
  contraction, 957–958
  genetic variations in, 960
  immediate, 955
  insulin resistance and, 957
  metabolic changes in, 958–960
  molecular mechanisms in, 957–960
  substrate oxidation in, 955–957
Muscle sympathetic nervous system activity, in hypertension, 906

N
Naltrexone, 1003
National Cholesterol Education Program Adult Treatment Panel
  guidelines of, 927–928
  metabolic syndrome definition of, 856, 893
National Health and Nutrition Examination Survey data, on hypertension, 903–904
National Heart, Lung and Blood Institute, metabolic syndrome criteria of, 857–858
National Weight Control Registry, on weight maintenance, 945–946, 981
Neuropeptide Y receptor antagonists, 1002
Niacin, for dyslipidemia, 866

O
Obesity
  apparent healthy individuals with, 884–885
  cardiovascular disease in. See Cardiovascular disease.
  dyslipidemia and, 893–902
  hypertension in, 903–917
  insulin resistance and. See Insulin resistance.
  metabolic syndrome and, 855–873, 927–928
  treatment of
Obesity (continued)
  cognitive and behavioral approaches to, 971–988
dietary, 939–952
  exercise in. See Exercise.
  medications for, 989–1008
  surgical, 1009–1030
Obstructive sleep apnea
  cardiovascular disease in, 930
  hypertension in, 911–912
Orlistat, 991, 994–996
  for metabolic syndrome, 865–866
Ornish diet, 942

P
Pancreatic lipase inhibitors, 1003
Pediatric patients, coronary artery disease in, 920–921
Peptide YY, after bariatric surgery, 1025
Peroxisome proliferator activated-receptor(s)
  exercise and, 958
  in metabolic syndrome, 861–864
Peroxisome proliferator activated-receptor coactivator, in metabolic syndrome, 958–959
Phendimetrazine, 991, 993–994
Phentermine, 991, 993–994, 1003
Phosphatidylinositol 3 kinase, in metabolic syndrome, 861
Physical activity. See Exercise.
Pioglitazone, 919
Plasminogen activator, in cardiovascular disease, 930
Pramlintide, 999
Pro-opiomelanocortin, lipid metabolism regulation in, 898

R
Reactive oxygen species
  in hypertension, 908
  in metabolic syndrome, 862–863
Reaven definition, of metabolic syndrome, 858–859
Relapse, prevention of, 975
Renin angiotensin aldosterone system, in hypertension, 905–906
Resistin
  in dyslipidemia, 898
  in hypertension, 908–909
  in metabolic syndrome, 864
Retinol binding protein 4, in metabolic syndrome, 863
Rimonabant
  for metabolic syndrome, 865–866
  for weight loss, 1000–1002
Roux-en-Y gastric bypass, 1012–1014, 1020
S

Second Joint Task Force of European and other Societies on Coronary Prevention, metabolic syndrome definition of, 856
Self-monitoring, in cognitive-behavioral therapy, 973–974
Serotonin 2C receptor agonists, 1002–1003
Sertraline, 996–997
Sibutramine
  for metabolic syndrome, 865–866
  for obesity, 990–993
Sleep apnea, obstructive
  cardiovascular disease in, 930
  hypertension in, 911–912
Sleeve gastrectomy, 1015, 1017
Sodium, renal regulation of, in hypertension, 907–908
Statins, for dyslipidemia, 866, 927
Stimulus control, in cognitive-behavioral therapy, 974
Surgery. See Bariatric surgery.
Survival paradox, 924–925
Sympathetic nervous system, in hypertension, 906
Sympathomimetic drugs, 993–994

T

Takeda compounds, 1003
Thiazolidinediones, 919
Topiramate, 997–998, 1003
Triglycerides
  in metabolic syndrome, 855–858
  intramuscular, exercise and, 955–959
  metabolism of, 894–895
Tumor necrosis factor-α, in metabolic syndrome, 862–864

U

University HealthSystem Consortium, bariatric surgery outcomes of, 1016

V

Vertical banded gastroplasty, 1012
Veterans Affairs HDL Intervention trial, 927–928

W

Waist circumference, in metabolic syndrome, 859–860
Weight loss
  bariatric surgery for, 1009–1030
  diabetes mellitus remission in, 1023–1024
  diet for, 939–952
  drugs for, 989–1008
  exercise for, 940–941, 953–969
Weight (continued)
   insulin resistance changes in, 885–888
Weight Watchers diet, 942
Wisconsin Sleep Cohort Study, 911
World Health Organization, metabolic syndrome definition of, 856

Z
Zone diet, 942
Zonisamide, 998